Human Abuse Potential of the New Opioid Analgesic Molecule NKTR-181 Compared with OxycodoneLynn R. Webster, Michael A. Eldon, Carlo J. Di Fonzo et al.|Pain Medicine|2016Cited by 29
Abstract 1617: Mechanistic modeling of a new kinetically-controlled CD122 agonist for cancer immunotherapy: NKTR-214 pharmacokinetics, pharmacodynamics, and receptor pharmacologySamira Khalili, Ute Hoch, Michael A. Eldon et al.|Cancer Research|2017Cited by 0
P124 - Molecular determinants of the inherently slow entry of NKTR-181 into the brainAleksandrs Odinecs, Stephen K. Doberstein, Werner Rubas et al.|Drug Metabolism and Pharmacokinetics|2020Cited by 0